Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrx Asks FDA To Reconsider Petition To Block Biovail Diltiazem ER Generic

Executive Summary

Andrx is petitioning FDA to reconsider its denial of the firm's previous citizen's petition in an effort to prevent market entry of Biovail's generic version of Hoechst Marion Roussel's Cardizem CD after expiration of Andrx' exclusivity Dec. 19.

You may also be interested in...

Citizen Petitions Cannot Be Used To Block Generics - FDA Proposed Rule

Innovator pharmaceutical companies will not be able to block approval of generic drugs by using the citizen petition mechanism, according to FDA's Nov. 30 proposed rule to revise the petition process.

Andrx Generic Diltiazem Will Launch After Hoechst Patent Suit Settlement

Andrx will launch a reformulated once-daily diltiazem product following the resolution of a patent suit with Cardizem CD manufacturer Hoechst Marion Roussel.

Biovail Tiazac Market Share Is Significant Enough To Be Reference Drug - FDA

Forest/Biovail's Tiazac extended-release diltiazem will be relisted in the Orange Book as a reference listed drug, allowing submission of ANDAs for the brand.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts